INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEONEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To KnowA number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEONEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To KnowA number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product LaunchesOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year revenue guidance of $723 million at the midpoint came in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEONEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Why NeoGenomics (NEO) Stock Is Trading Up TodayShares of oncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO)
jumped 4.8% in the afternoon session after news of a significant insider purchase by a key executive. The move followed the disclosure of an insider purchase by Jeffrey Sherman, the Chief Financial Officer of a company subsidiary. Sherman acquired 20,000 shares, a transaction often interpreted by investors as a strong signal of confidence in a company's prospects. This positive development appeared to outweigh the more cautious sentiment from Wall Street, where a consensus of analysts rated the stock as a "Hold." Investors seemingly focused on the executive's bullish action rather than recent negative headlines, including a law firm's investigation into the company's prior financial reporting.
1 Small-Cap Stock with Exciting Potential and 2 We IgnoreSmall-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEONEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEONEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
NeoGenomics, Inc. (
NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company’s PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable.
Why NeoGenomics (NEO) Shares Are Falling TodayShares of oncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO)
fell 20.2% in the morning session after the company reported second-quarter results that included a significant cut to its full-year financial guidance, sparking a selloff.
NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8%Oncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year revenue guidance of $723 million at the midpoint came in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.
NeoGenomics Reports Second Quarter 2025 Results
NeoGenomics, Inc. (
NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025.
NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of EarningsOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO)
will be reporting earnings this Tuesday before market hours. Here’s what to expect.
3 of Wall Street’s Favorite Stocks We’re Skeptical OfThe stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To KnowA number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
3 Stocks Under $10 We’re Skeptical OfStocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
